SCHEMBL9909759

SCHEMBL9909759

Nc1nccc(Oc2ccccc2)c1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 1/20 0.47
TTR P02766 1/20 0.47
ALB P02768 1/20 0.47
THRB P10828 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAPT P10636 9/20 0.46
LMNA P02545 5/20 0.45
ALDH1A1 P00352 2/20 0.42
TP53 P04637 1/20 0.42
HTT P42858 4/20 0.41
KDM4E B2RXH2 1/20 0.41
MITF O75030 1/20 0.41
NOD2 Q9HC29 1/20 0.41
MGMT P16455 1/20 0.41
TLR4 O00206 1/20 0.40
TLR2 O60603 1/20 0.40
PIN1 Q13526 1/20 0.40
TNK2 Q07912 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4462548 0.88 MAPT (0.48) SMN1; SMN2MEN1KMT2ATDP1MAPT
SCHEMBL1793013 0.86 ALDH1A1 (0.52) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL13603224 0.85 LMNA (0.63) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL4464895 0.84 KDR (0.52) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL12616280 0.84 MAPT (0.66) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL11191625 0.83 ALDH1A1 (0.48) SMN1; SMN2MEN1TTRALBTHRB
SCHEMBL13603417 0.83 BRAF (0.57) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL13603277 0.83 MAPT (0.50) SMN1; SMN2MAPTLMNAALDH1A1TP53
SCHEMBL4458366 0.82 ALDH1A1 (0.40) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL2937186 0.82 PDGFRA (0.45) SMN1; SMN2MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540372-B2 Pyrido[2,3-b]pyrazin-8-substituted compounds and their use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2017-01-10 US disclosed
CN-103435561-B A kind of Novel D-amino acid oxidase inhibitor and preparation thereof and application 上海交通大学 2016-08-10 CN disclosed
US-20160002230-A1 PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-01-07 US disclosed
US-9155737-B2 Pyrido[2,3-B]pyrazin-8-substituted compounds and their use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-10-13 US disclosed
US-20150182526-A1 PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-07-02 US disclosed
US-8912191-B2 Pyrido[2,3-B]pyrazin-8-substituted compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-12-16 US disclosed
US-20140121212-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2014-05-01 US disclosed
CN-103435561-A Novel D-amino acid oxidase inhibitor and preparation and application thereof UNIV SHANGHAI JIAOTONG 2013-12-11 CN disclosed
US-8546387-B2 Pyrido[2,3-b]pyrazin-8-substituted compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-10-01 US disclosed
US-20120238568-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2012-09-20 US disclosed
US-8198279-B2 Pyrido[2,3-b]pyrazin-8-substituted compounds and their use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2012-06-12 US disclosed
US-20100298320-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238568-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use BRAF, NRAS, RAF1 SMN1; SMN2 4162/4885MEN1 3020/4885TTR 1948/4885
US-20150182526-A1 PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE BRAF, NRAS, RAF1 SMN1; SMN2 4162/4885MEN1 3020/4885TTR 1948/4885
US-20160002230-A1 PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE BRAF, NRAS, RAF1 SMN1; SMN2 4162/4885MEN1 3020/4885TTR 1948/4885
US-20140121212-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use BRAF, NRAS, RAF1 SMN1; SMN2 4162/4885MEN1 3020/4885TTR 1948/4885
US-20100298320-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use BRAF, NRAS, RAF1 SMN1; SMN2 4162/4885MEN1 3020/4885TTR 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.